DE602005019547D1 - "verfahren und zwischenprodukte zur herstellung von statinen; insbesondere von rosuvastatin" - Google Patents

"verfahren und zwischenprodukte zur herstellung von statinen; insbesondere von rosuvastatin"

Info

Publication number
DE602005019547D1
DE602005019547D1 DE200560019547 DE602005019547T DE602005019547D1 DE 602005019547 D1 DE602005019547 D1 DE 602005019547D1 DE 200560019547 DE200560019547 DE 200560019547 DE 602005019547 T DE602005019547 T DE 602005019547T DE 602005019547 D1 DE602005019547 D1 DE 602005019547D1
Authority
DE
Germany
Prior art keywords
formula
compound
group
protecting
protecting group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200560019547
Other languages
English (en)
Inventor
David John Moody
Jonathan William Wiffen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bradford Pharma Ltd
Original Assignee
Avecia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avecia Pharmaceuticals Ltd filed Critical Avecia Pharmaceuticals Ltd
Publication of DE602005019547D1 publication Critical patent/DE602005019547D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30Oxygen atoms, e.g. delta-lactones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE200560019547 2004-03-26 2005-03-23 "verfahren und zwischenprodukte zur herstellung von statinen; insbesondere von rosuvastatin" Active DE602005019547D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0406757A GB0406757D0 (en) 2004-03-26 2004-03-26 Process and compounds
PCT/GB2005/001099 WO2005092867A2 (en) 2004-03-26 2005-03-23 Process and intermediate compounds useful in the preparation of statins, particularly rosuvastatin

Publications (1)

Publication Number Publication Date
DE602005019547D1 true DE602005019547D1 (de) 2010-04-08

Family

ID=32188702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200560019547 Active DE602005019547D1 (de) 2004-03-26 2005-03-23 "verfahren und zwischenprodukte zur herstellung von statinen; insbesondere von rosuvastatin"

Country Status (21)

Country Link
US (2) US8703945B2 (de)
EP (2) EP1729775B1 (de)
JP (1) JP5016478B2 (de)
KR (1) KR20060130765A (de)
CN (1) CN101022807B (de)
AT (2) ATE458484T1 (de)
AU (1) AU2005225602A1 (de)
BR (1) BRPI0507999A (de)
CA (1) CA2561059C (de)
CY (2) CY1110091T1 (de)
DE (1) DE602005019547D1 (de)
DK (2) DK1729775T3 (de)
ES (2) ES2379481T3 (de)
GB (1) GB0406757D0 (de)
HR (1) HRP20100287T1 (de)
IL (1) IL178274A0 (de)
PL (2) PL1729775T3 (de)
PT (2) PT1729775E (de)
RS (1) RS51306B (de)
SI (2) SI1729775T1 (de)
WO (1) WO2005092867A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100349877C (zh) 2001-07-13 2007-11-21 阿斯特拉曾尼卡英国有限公司 氨基嘧啶化合物的制备方法
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
GB0406757D0 (en) * 2004-03-26 2004-04-28 Avecia Ltd Process and compounds
GB0427491D0 (en) 2004-12-16 2005-01-19 Avecia Ltd Process and compounds
CN101208307B (zh) * 2005-06-24 2012-10-17 力奇制药公司 制备不含杂质的无定型罗苏伐他汀钙的方法
EP1978020A1 (de) * 2007-04-03 2008-10-08 LEK Pharmaceuticals D.D. Verfahren zur Herstellung von Statinen, insbesondere von Rosuvastatin, und Zwischenprodukt für deren Herstellung
US8183397B2 (en) 2007-04-03 2012-05-22 Lek Pharmaceuticals D.D. Synthesis of statins
CA2713009C (en) 2008-01-23 2018-08-28 Lek Pharmaceuticals D.D. ((2s,4r)-4,6-dihydroxytetrahydro-2h-pyran-2-yl)methyl carboxylate and process for the production thereof
AU2013202895B2 (en) * 2009-03-10 2014-09-18 Redx Pharma Plc Rosuvastatin and atorvastatin derivatives
GB0904102D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of atorvastatin lactols as medicaments
GB0904100D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Use of rosuvastatin lactols as medicaments
GB0904104D0 (en) * 2009-03-10 2009-04-22 Bradford Pharma Ltd Atorvastatin and rosuvastatin derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474971A (en) * 1982-09-29 1984-10-02 Sandoz, Inc. (Tetrahydropyran-2-yl)-aldehydes
US4625039A (en) * 1983-12-21 1986-11-25 Sandoz Pharm. Corp. 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4677211A (en) 1984-06-29 1987-06-30 Sandoz Pharmaceuticals Corp. Preparation of lactones
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5795749A (en) 1995-04-05 1998-08-18 The Scripps Research Institution Use of 2-deoxyribose-5-phosphate aldolase to prepare 2-deoxyfucose, analogues and derivatives
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
WO2001022962A1 (en) * 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
DE10216967A1 (de) 2002-04-16 2003-11-13 Bayer Ag Verfahren zur Herstellung spezieller aromatischer Aldehyde
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005040134A1 (en) * 2003-10-22 2005-05-06 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
GB0406757D0 (en) * 2004-03-26 2004-04-28 Avecia Ltd Process and compounds

Also Published As

Publication number Publication date
EP1958633B1 (de) 2011-12-14
PL1729775T3 (pl) 2011-03-31
US9024025B2 (en) 2015-05-05
IL178274A0 (en) 2006-12-31
AU2005225602A1 (en) 2005-10-06
JP2007530521A (ja) 2007-11-01
PT1729775E (pt) 2010-05-27
US8703945B2 (en) 2014-04-22
ATE458484T1 (de) 2010-03-15
GB0406757D0 (en) 2004-04-28
JP5016478B2 (ja) 2012-09-05
US20140316135A1 (en) 2014-10-23
PT1958633E (pt) 2012-03-27
ES2341658T3 (es) 2010-06-24
EP1958633A3 (de) 2008-08-27
CN101022807B (zh) 2012-05-09
ES2379481T3 (es) 2012-04-26
WO2005092867A3 (en) 2005-11-10
RS51306B (sr) 2010-12-31
CA2561059A1 (en) 2005-10-06
CN101022807A (zh) 2007-08-22
SI1958633T1 (sl) 2012-05-31
EP1958633A2 (de) 2008-08-20
BRPI0507999A (pt) 2007-07-31
SI1729775T1 (sl) 2010-07-30
CA2561059C (en) 2013-12-24
CY1110091T1 (el) 2015-01-14
CY1115040T1 (el) 2016-12-14
HRP20100287T1 (hr) 2010-07-31
DK1958633T3 (da) 2012-04-02
ATE536875T1 (de) 2011-12-15
DK1729775T3 (da) 2010-06-07
PL1958633T3 (pl) 2012-12-31
US20080281101A1 (en) 2008-11-13
EP1729775B1 (de) 2010-02-24
EP1729775A2 (de) 2006-12-13
KR20060130765A (ko) 2006-12-19
WO2005092867A2 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
DE602005019547D1 (de) "verfahren und zwischenprodukte zur herstellung von statinen; insbesondere von rosuvastatin"
BR0109922A (pt) Compostos quìmicos
ATE364651T1 (de) Polymerisationskatalysator für polyester, damit hergestellter polyester und verfahren zur herstellung von polyester
ATE444747T1 (de) Verfahren zur herstellung von expoxybutanol- zwischenprodukten
DE502005001385D1 (de) Verfahren zur herstellung von aminen aus carbodiimidgruppen aufweisenden verbindungen durch hydrolyse mit wasser
ATE377593T1 (de) 9,10-alpha,alpha-oh-taxananaloga und verfahren zu deren herstellung
ATE442363T1 (de) Verfahren zur herstellung von pyridinverbindungen
DE60309251D1 (de) Verfahren zur Herstellung von Donepezil
ATE524505T1 (de) Polymerisierbare zusammensetzung und flachdruckplattenvorläufer damit, alkalilösliches polyurethanharz sowie verfahren zur herstellung einer diolverbindung
DE60125378D1 (de) Verfahren zur herstellung von 2-aminomethyl-halogen-pyridinen
DE602006012622D1 (de) Verfahren zur herstellung von 1,1,1-tris(4-hydroxyphenyl)alkanen
ATE492523T1 (de) Verfahren zur herstellung von halogensubstituiertem benzoldimethanol
DK1598358T3 (da) Forbindelser indeholdende 3,4-methylendioxythiophen-enheder
ATE393187T1 (de) Verfahren zur modifizierung eines fluorpolymersubstrats und dadurch erhaltene verbundgegenstände
DE602005022213D1 (de) Verfahren zur herstellung von phenyl-2-pyrimidinyl-ketonen und neuen zwischenprodukten daraus
ATE444323T1 (de) Neuartige epoxidverbindungen und verfahren zu ihrer herstellung
ATE279422T1 (de) Verfahren zur herstellung von 1-hydroxy-1, 1- diphosphonsäureverbindungen
ATE293095T1 (de) Verfahren zur herstellung von cyclopropancarboxylaten
DE60141724D1 (de) Methode zur Herstellung von Diazaphosphacyclen
DE602004031727D1 (de) Neues verfahren und zwischenprodukte zur herstellung von 19-nor-steroiden
DE502006002384D1 (de) Verfahren zur herstellung von tetracarbonsäuren
DE60306361D1 (de) Verfahren zur herstellung von benazeprilhydrochloride
DE602004023633D1 (de) Verfahren zur herstellung von 2,3,6,7,10,11-hexahydroxytriphenylen
ATE375335T1 (de) Verfahren zur herstellung von n-glycidylaminen
DE602005001507D1 (de) Verfahren zur herstellung von diiminverbindungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BRADFORD PHARMA LTD., WIGAN, LANCASHIRE, GB

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1729775

Country of ref document: EP

Representative=s name: PATENTANWAELTE FREISCHEM, 50677 KOELN, DE